<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article273</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/RITUXVAS" style="display:block; margin-bottom:10px;">RITUXVAS Original</a></li>
<h2><strong>RITUXVAS</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Rituximab versus Cyclophosphamide in ANCA-Associated Vasculitis".The New England Journal of Medicine. 2010. 363:211-220.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1Clinical Question<br/>
2Bottom Line<br/>
3Major Points<br/>
4Guidelines<br/>
5Design<br/>
6Population<br/>
6.1Inclusion Criteria<br/>
6.2Exclusion Criteria<br/>
6.3Baseline Characteristics<br/>
7Interventions<br/>
8Outcomes<br/>
8.1Primary Outcomes<br/>
8.2Secondary Outcomes<br/>
9Criticisms<br/>
10Funding<br/>
11Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with newly diagnosed ANCA-associated vasculitis and renal involvement, is rituximab-based regimen superior to standard intravenous cyclophosphamide for inducing sustained remission?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
A rituximab-based regimen was not found to be superior to standard intravenous cyclophosphamide treatment in inducing sustained remission for ANCA-associated vasculitis, maintaining high remission rates in both groups without reducing early severe adverse events.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of August 2021, no guidelines reflecting the results of this trial have been described.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Open-label, parallel-group, randomized trial<br/>
N=44 patients with newly diagnosed ANCA-associated vasculitis and renal involvement<br/>
Rituximab group (n=33)<br/>
Control group (standard intravenous cyclophosphamide followed by azathioprine) (n=11)<br/>
Setting: 8 centers in Europe and Australia<br/>
Enrollment: June 2006 to June 2007<br/>
Mean follow-up: 12 months<br/>
Primary endpoints: Sustained remission rates at 12 months, severe adverse events<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
New diagnosis of ANCA-associated vasculitis<br/>
ANCA positivity<br/>
Renal involvement with necrotizing glomerulonephritis on biopsy or red-cell casts/hematuria on urinalysis<br/>
<br/>
Exclusion Criteria<br/>
Not described<br/>
<br/>
Baseline Characteristics<br/>
Median age: 68 years<br/>
Glomerular filtration rate (GFR): 18 ml per minute per 1.73 m²<br/>
Use of plasma exchange balanced between groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Rituximab group: Intravenous rituximab at 375 mg/m² for 4 weeks with two intravenous cyclophosphamide pulses, without azathioprine<br/>
Control group: Intravenous cyclophosphamide for 3-6 months followed by azathioprine<br/>
Both groups received standard glucocorticoid regimen<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
Sustained remission<br/>
Rituximab group: 76%<br/>
Control group: 82% (P=0.68)<br/>
Severe adverse events<br/>
Rituximab group: 42%<br/>
Control group: 36% (P=0.77)<br/>
<br/>
Secondary Outcomes<br/>
Time to remission: Similar between groups<br/>
Change in GFR: Median increase, rituximab group = 19 ml/min; control group = 15 ml/min (P=0.14)<br/>
Prednisolone dose: Similar reduction in both groups<br/>
Quality of life (SF-36): Improvement in both groups, but rituximab group showed a significant improvement in the mental component (P=0.04), with two outliers influencing results<br/>
Vasculitis Damage Index: Changes similar between groups<br/>
Relapse: 15% in rituximab group, 10% in control group (P=0.70)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
The trial did not determine long-term efficacy and safety beyond 12 months, and long-term benefits of rituximab remain uncertain.<br/>
The trial's relatively small sample size and open-label design could potentially introduce bias.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Cambridge University Hospitals National Health Service Foundation Trust, F. Hoffmann–La Roche with provision of rituximab, and a research grant contributing to trial costs.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Original publication in The New England Journal of Medicine (2010): [PubMed•Full text•PDF]
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
